MEN1 and acute myeloid leukemia: In addition, large phase 3 randomized clinical trials of AZA + VEN with placebo or revumenib (HOVON group, NCT06652438), ziftomenib (KOMET-017-NIC, NCT07007312), or bleximenib (cAMeLot-2, NCT06852222) will hopefully definitively address the role of menin inhibitor triplets in the treatment of NPM1mut and KMT2Ar AML.